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Abstract
Background: Tamoxifen (TAM) is a well characterized breast cancer drug and selective estrogen
receptor modulator (SERM) which also has been associated with a small increase in risk for uterine
cancers. TAM's partial agonist activation of estrogen receptor has been characterized for specific
gene promoters but not at the genomic level in vivo.Furthermore, reducing uncertainties associated
with cross-species extrapolations of pharmaco- and toxicogenomic data remains a formidable
challenge.
Results: A comparative ligand and species analysis approach was conducted to systematically
assess the physiological, morphological and uterine gene expression alterations elicited across time
by TAM and ethynylestradiol (EE) in immature ovariectomized Sprague-Dawley rats and C57BL/6
mice. Differential gene expression was evaluated using custom cDNA microarrays, and the data
was compared to identify conserved and divergent responses. 902 genes were differentially
regulated in all four studies, 398 of which exhibit identical temporal expression patterns.
Conclusion: Comparative analysis of EE and TAM differentially expressed gene lists suggest TAM
regulates no unique uterine genes that are conserved in the rat and mouse. This demonstrates that
the partial agonist activities of TAM extend to molecular targets in regulating only a subset of EE-
responsive genes. Ligand-conserved, species-divergent expression of carbonic anhydrase 2 was
observed in the microarray data and confirmed by real time PCR. The identification of comparable
temporal phenotypic responses linked to related gene expression profiles demonstrates that
systematic comparative genomic assessments can elucidate important conserved and divergent
mechanisms in rodent estrogen signalling during uterine proliferation.
Background
The estrogen receptor (ER) is a master transcriptional reg-
ulator involved in the proliferation and differentiation of
many tissues, most notably the female reproductive tract.
It functions as a ligand-dependent transcription factor
with two activation functions (AF-1 and AF-2) which
interact with cofactors (SRC-1, GRIP1, CBP/p300) to
modulate transcription using different mechanisms [1,2].
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The genomic activities of ER are mediated via direct DNA
binding at estrogen response elements (EREs) or through
indirect tethering mechanisms involving AP-1, Sp1, or Nf-
κB [3]. It also has been shown to use non-genomic mech-
anisms via membrane associated ERs which activate vari-
ous protein kinase cascades [4]. Furthermore, two distinct
ER isoforms exist which have divergent functionality as
well as tissue- and cell type-specific expression. For exam-
ple, whereas mammary tissue expresses both ERα and ERβ
[5] at comparable levels in different cells, the uterus pre-
dominantly expresses ERα.
Tamoxifen (TAM) is a well characterized breast cancer
drug and prophylactic that is a selective estrogen receptor
modulator (SERM). SERMs are structurally diverse com-
pounds that bind the ER and elicit ligand- and tissue-spe-
cific effects [6,7], such as inhibiting the proliferative
effects of estrogen in ER-positive breast cancers, while
maintaining partial agonistic activity in other tissues [8].
SERM binding causes a unique conformation in the ER
ligand binding domain which alters the apposition of ER
helix 12 and function of AF-2 relative to 17β-estradiol
(E2), while still allowing for the ligand-independent func-
tionality of AF-1 [9].
TAM-induced ER-mediated gene expression has been
characterized on a promoter/gene specific basis [10,11].
However, the effect of TAM on global uterine gene expres-
sion has not been comprehensively examined. Whether or
not the modulation of helix 12/AF-2 by TAM results in
merely decreased efficacy or specificity for typical ER gene
targets or potentiates unique cofactor interactions and
thus novel genomic targets has not been fully examined.
Therefore, elucidating the genomic targets of TAM is
important to the understanding of SERM-ER proliferative
activities, especially due to its association with uterine
cancer following continuous treatment [12], which is cur-
rently understood to be a function of its partial agonist
activity.
The classic rodent uterotrophic assay to assess the estro-
genic potential of a chemical examines both the physio-
logical and histomorphological endpoints in the uterus
[13]. Uterine wet weight, water imbibition and luminal
epithelial cell height induction are typically evaluated
after three consecutive daily treatments [14]. This assay
can be extended by including temporal gene expression
analysis, which can be anchored to these more apical end-
points in order to provide a more comprehensive assess-
ment of the molecular and physiological effects of
treatment [15,16].
Furthermore, this enriched assessment can also be used to
evaluate the ability of surrogate models to accurately pre-
dict human responses to drugs, industrial chemicals, nat-
ural products and environmental contaminants. In the
case of tamoxifen metabolism rats have been shown to
exhibit a metabolic profile more similar to humans than
mice [17,18]. Thus elucidating the dose-responsive and
temporal effects of tamoxifen on gene expression will
inform the relative importance of this divergence in
rodent metabolic profile. Furthermore, elucidating spe-
cies-specific differences in both rats and mice for either
gene function or regulation is also an important factor for
reducing uncertainties associated with cross-species
extrapolation of data in risk assessment. Therefore, a
cross-species comparative method was employed to
examine temporal gene expression in rodents during TAM
and ethynylestradiol (EE) induced uterotrophy in order to
better understand the early molecular events associated
with tamoxifen-related uterine cancers in humans.
Results
Uterine Wet Weight (UWW) and Water Content
Increases in UWW were used to evaluate the responsive-
ness to EE and TAM. Dose response studies were per-
formed using 0.01, 0.1, 1, 10, 100, 300 μg/kg b.w. EE, and
3, 10, 30, 100, 300, 1000, 3000 μg/kg b.w. TAM. In each
case, 100 μg/kg approached the maximum uterotrophic
response and this dose was subsequently used for the time
course studies (Figure 1). Whereas TAM was equipotent to
EE in eliciting uterotrophy in C57BL/6 mice and Sprague-
Dawley rats, it was 43% less efficacious in both species
eliciting only 4- and 5-fold induction (in the rat and
mouse, respectively) compared to the ~9-fold increase
induced by EE. In the time course studies, 100 μg/kg of EE
or TAM was orally administered once daily for three con-
Dose Response Uterine Wet Weights (UWW) Figure 1
Dose Response Uterine Wet Weights (UWW). 
UWW was measured across several EE and TAM doses in 
the mouse and rat. A plot of the fold change increase in wet 
weight is plotted. A dose response curve was fit to the data 
(GraphPad 4.0) to estimate EC50 values. 100 μg/kg b.w. 
approximates the maximum response in all four cases and 
was used in subsequent time course studies. ED50 values 
were comparable between ligands in the rat while exhibiting 
only a two fold difference in the mouse, indicating conserva-
tion of sensitivity to EE and TAM.
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secutive days. UWW and water content changes were
measured at each time point [see Additional File 1 and 2].
EE induced UWW increases only at 24 and 72 hrs in the
mouse, while in the rat the classic water imbibition
response occurred between 4 and 12 hrs followed by max-
imum induction at 72 hrs. TAM induction of water imbi-
bition was delayed approximately 8 hrs in the rat and
subdued in both (45% and 65% of EE in rat and mouse,
respectively). The increases in uterine water content sug-
gest that early increases in UWW are due at least in part to
this water imbibition. As in the wet weight, the changes in
water content after TAM treatment temporally lagged
behind EE and were notably less efficacious. Therefore,
the large difference in wet weight between EE and TAM at
72 hrs is possibly due to early differences in gene expres-
sion responsible for water imbibition.
Histomorphology
Induction of luminal epithelial height (LEH) is a classic
estrogen response [19,20] in the rodent uterus. No
increases in LEH were observed in any group between 2
and 12 hrs (Figure 2). However, EE induced LEH as early
as 18 hrs in the mouse and 24 hrs in the rat. While EE and
TAM produced comparable levels of LEH induction (~2.6-
fold) in the mouse at 72 hrs, TAM treatment in the rat elic-
ited a significantly greater LEH increase (p < 0.05, 4.4-fold
for TAM and 2.6-fold for EE). EE induced moderate to
marked stromal edema beginning as early as 4 and 8 hrs
while TAM induced severe stromal and myometrial
edema at 12 hrs. Proliferative indices (number of mitotic
bodies) were noted in EE treated uteri at 18 and 24 hrs but
not detected in TAM treated samples. Moderate to severe
hyperplasia and hypertrophy in the stroma and epithe-
lium were present at 72 hrs in all studies. There was mild
apoptotic cell death in the epithelium in TAM studies at
72 hrs while mild to marked apoptosis was noted in EE
samples. The species difference in uterine architecture
(luminal invaginations seen in the mouse but not rat) pre-
viously observed [21] at 72 hrs was not as pronounced in
TAM treated samples.
Comparative Species and Ligand Analysis of Gene 
Expression
Global gene expression changes with respect to VEH con-
trols were measured and compared across time for MmEE,
MmTAM, RnEE, and RnTAM treatments. Pair-wise com-
parisons between compounds per species and between
species per compound were made to investigate conserved
responses. A two-tiered, bipartite (P1(t) and fold change)
approach was used to screen for conserved differentially
expressed genes (Figure 3).
In the mouse, 3,663 and 2,821 genes were differentially
regulated by EE and TAM respectively, with 2,631 com-
mon differentially expressed genes across all time points
(Figure 3B). These 2,631 common, differentially
expressed genes were then further examined to assess the
similarity of their EE- and TAM-elicited temporal expres-
sion profiles by comparing their expression profiles in
order to assess similarity between the treatments (Figure
3C). This comparison is comparable to a correlation anal-
ysis in assessing the similarity of statistically significant
differential gene expression relative to a control elicited by
EE and TAM. Each differentially expressed gene was desig-
nated as either coactive-similar direction (CAS), coactive-
divergent direction (CAD), displaced active-similar direc-
tion (DAS), or displaced active-divergent direction (DAD)
based on the relationship between the time and direction
of differential regulation, and the significance (P1(t)) of
the expression profile relative to the VEH control. For
Temporal Changes in Luminal Epithelial Height (LEH) Figure 2
Temporal Changes in Luminal Epithelial Height (LEH). LEH was quantified for each treatment group and compared to 
VEH controls. LEH induction was temporally delayed in response to TAM treatment in both species. Mouse induction was 
comparable between ligands while TAM-induced LEH was significantly (p < 0.05) greater than EE in rats.
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example, Igf1 is designated as CAS in the rat because it was
up regulated in a similar temporal pattern by both EE and
TAM between 12–24 hrs, while Junb was designated DAS
because although it was up regulated by both compounds,
EE induction was at 4 hrs but TAM treatment temporally
shifted the induction to 12 hrs. These designations assist
in developing gene lists and provide a preliminary assess-
ment of the similarity in gene expression profile on a
qualitative level that takes into account the statistical dif-
ference from VEH which typically is not considered in cor-
relation analyses. Using this approach, > 85% of EE and
TAM induced genes were designated as CAS (2255 genes).
Only a few were categorized as CAD or "divergently regu-
lated" (28 genes, 1% of the overlap).
Similarly in the rat, 2,284 and 2,087 genes were differen-
tially expressed by EE and TAM, respectively, resulting in
1,950 commonly regulated genes (Figure 3B). In both
species, roughly 93% of TAM-regulated genes overlapped
with EE. Of the 1,950 genes differentially expressed by
both EE and TAM in the rat, 86% (1,686 genes) were des-
ignated as CAS while only 23 were CAD. Comparison of
Comparative Analysis of Species-Conserved, Ligand-Specific Gene Expression Figure 3
Comparative Analysis of Species-Conserved, Ligand-Specific Gene Expression. (A) cDNA microarrays were used 
containing 13,361 mouse clones representing 8,734 unique genes and 8,507 rat clones representing 5,684 unique genes. (B) 
Differentially expressed genes regulated by each ligand were identified using relaxed criteria to minimize the likelihood of false-
negatives that marginally failed to meet the selection criteria. Differentially expressed genes elicited by both EE and TAM were 
analyzed for similarity in their temporal profiles by comparative analysis. Genes were designated as either CoActive-Similar 
direction (CAS), CoActive-Divergent direction (CAD), Displaced Active Similar direction (DAS), or Displaced Active Diver-
gent direction (DAD) based on the relationship between the time and direction of differential regulation, and the significance 
(P1(t)) of the expression profile relative to the VEH control. (C) The comparative results were plotted on a coordinate corre-
lation graph. A majority of genes show positive correlation between ligands for both fold change and P1(t) value. (D) Cross 
species analysis of ligand-divergent (CAD) expression profiles indicate no conservation.
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the 28 mouse CAD genes to the 23 rat CAD genes found
no overlapping orthologs (Figure 3D), suggesting that
there are no conserved differentially regulated genes for
which EE and TAM elicit divergent uterine responses in
the rat and mouse.
Comparison of Orthologous Gene Expression
A comparable approach was used to examine the cross-
species differential gene expression effects of EE and TAM
on orthologous rat and mouse genes. 3,417 unique
orthologous genes were represented on the rat and mouse
array platforms as determined by NCBI's HomoloGene
database (Figure 4A). In response to EE treatment, 2,095
and 2,181 of the 3,417 orthologous genes were differen-
tially expressed in the mouse and rat, respectively, with
1,634 orthologs differentially expressed in both species
(~75%) (Figure 4B). These 1,634 differentially expressed
orthologs were analyzed for coactivity of which 1,116
Comparative Analysis of Ligand-Conserved, Species-Specific Gene Expression Figure 4
Comparative Analysis of Ligand-Conserved, Species-Specific Gene Expression. (A) cDNA microarrays were used 
containing 13,361 mouse clones representing 8,734 unique genes and 8,507 rat clones representing 5,684 unique genes. There 
were 3,417 orthologous genes represented on the mouse and rat cDNA microarrays as determined by HomoloGene. (B) Dif-
ferentially expressed genes were assessed for similar expression patterns using relaxed criteria (|fold change| > 1.3; P1(t) > 
0.99) to minimize the likelihood of false-negatives that marginally failed to meet the selection criteria. (C) Common differen-
tially expressed orthologous genes were examined for comparable expression patterns, and designated according to the coac-
tivity categories (CAS, CAD, DAS, DAD) as described in Figure 3. The results were plotted on a coordinate correlation graph. 
A high proportion of differentially expressed orthologs exhibited a positive correlation when considering both fold-change and 
P1(t). (D) Comparisons of species-divergent (CAD) expression profiles identified 35 genes that were differentially expressed in 
the mouse and the rat but exhibited putative divergent regulation elicited by EE and TAM.
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genes (68%) were designated as CAS and 206 CAD. Simi-
larly, 1,252 mouse and 1,441 rat genes were differentially
expressed following TAM treatment with 891 orthologs
differentially expressed in both species. 705 (79%) of
these were designated as CAS genes while 63 genes were
designated CAD. A comparison of the EE and TAM CAD
orthologs identified 35 genes that are divergently regu-
lated between the mouse and rat in response to both EE
and TAM. Of these 35 genes, 9 were represented by only a
single feature on the microarray for both species, 12 were
represented by 2 or more features in at least one species
that had poor internal correlation, and 14 were repre-
sented by 2 or more features in at least one species that
were internally consistent. Thus, a strength of evidence
approach was taken for pursuing genes exhibiting putative
divergent regulation with quantitative real time PCR.
QRT-PCR Verification of Microarray Data
The expression profiles of 25 genes (including known
estrogen responsive genes: Fos, C3, Calb3, Igf1, Sult1a1,
Aqp5, and Vegf) accounting for the spectrum of temporal
patterns and functional categories were verified by QRT-
PCR in either species or compound. In general there was
a good correlation between the QRT-PCR and microarray
results (data not shown).
Fourteen orthologs that exhibited putative divergent regu-
lation in the mouse compared to the rat following EE and
TAM treatment were further investigated. However, QRT-
PCR indicated that these genes exhibited either a CAS rela-
tionship between species or were inconclusive, except for
carbonic anhydrase 2 (designated Car2 in the mouse and
Ca2 in the rat and human, hereafter referred to as Ca2 to
represent all orthologs). QRT-PCR analysis of Ca2 con-
firmed the microarray data (correlation coefficient r =
0.95, 0.98, 0.82, and 0.78 for MmEE, MmTAM, RnEE and
RnTAM, respectively; Figure 5). These results were con-
firmed by two different sets of primers, with one set que-
rying species specific regions of the mouse and rat mRNA,
and the second set designed to amplify the same region in
both species using the same primers.
Four-Way Venn Analysis
Following pair-wise comparisons by chemical and spe-
cies, an integrated comparison of all four data sets was
performed where differentially expressed orthologous
genes (NCBI, HomoloGene) for each data set were
entered into the 4-way Venn Diagram Generator. The
number and identity of unique genes populating the over-
laps of each data set was determined for common
orthologs (Figure 6). The comparison of all four data sets
resulted in 902 genes being commonly regulated at any
time point (Venn subset I). Of the 902 overlapping genes,
398 exhibited a similar temporal profile (CAS) across all
four data sets, suggesting comparable modes of regulation
which we refer to as "orthologous expression". These
genes represented functional categories associated with
cellular proliferation and differentiation; hallmarks of
estrogen induced uterotrophy. Selected conserved exam-
ples exhibiting orthologous expression in terms of either
fold-change alone (Fos, C3, Igf1, Ca3, Sepp1) or large
increase in copy number, regardless of fold change
(Cd24a, Slc25a5, Krt13, Dcn, Itm2b) are provided in
Table 1.
Of interest are the 128 and 12 genes populating subsets B
and K, respectively. Subset B represents putative species-
conserved EE-specific responses, of which, less than 60%
exhibited similar direction of regulation (CAS or DAS des-
ignation) by TAM. Most of these genes were regulated by
TAM but did not meet the fold change or P1(t) selection
criteria, suggesting a potency issue rather than unique reg-
ulation. For example S100a8, a calcium binding protein,
was induced 1.5-fold (Mm) and 3.5-fold (Rn) by EE while
TAM only induced a 1.3-fold change in the mouse that did
not meet the statistical cutoff while in the rat the statistical
cutoff was achieved but induction was only 1.2-fold. Like-
wise, further analysis of the 12 species-conserved TAM-
specific responses revealed that only Myh6 (myosin,
heavy chain 6), a component of muscle fibre that is likely
expressed in the myometrium, exhibited an overlap in
temporal expression between species. However, compara-
ble expression is only observed at 72 hrs where secondary
and tertiary effects are likely to overlap. In addition, there
is insufficient data to exclude the possibility that Myh6 is
regulated by TAM via an ER-independent mechanism.
Collectively, these results suggest there are no species-con-
served, TAM-specific or -divergent genes which are regu-
lated in a separate manner when compared to EE in the
rodent uterus. Approximately 400 genes exhibited highly
conserved and correlated expression across all four data
sets, defining a robust gene set that is predictable and inte-
gral to ER-mediated uterotrophy in the rodent. However,
species-specific gene expression profiles are difficult to
assess and confirm given the complex orthologous rela-
tionships between the species specific array probe sets.
Many of the putative differences suggested may be attrib-
uted to differing probe sensitivities or representations
within respective genes. The lone identified exception is
the species-divergent regulation of Ca2 that is conserved
in response to both ER ligands and confirmed by homol-
ogous and species-specific QRT-PCR primer pairs.
Discussion
The uterotrophic response has been used as an acute assay
to assess the estrogenicity of a compound using both
physiological and cytoarchitectural endpoints. Our
extended design incorporates early monitoring of global
gene expression (2–24 hrs) to capture the ER-mediated
effects as well as subsequent secondary and tertiary
responses. Early gene expression was also examined forBMC Medical Genomics 2009, 2:19 http://www.biomedcentral.com/1755-8794/2/19
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conserved responses across ligand and species. The highly
parallel nature of the EE and TAM study designs and sub-
sequent analyses facilitated more robust comparisons,
thus increasing confidence in the identification of con-
served uterine responses between species and ligands.
EE and TAM doses were selected based on UWW dose
response studies which identified 100 μg/kg as the most
efficacious dose for each compound. Although differing
pharmacokinetics may account for discrepancies between
rodents and humans, 100 μg/kg TAM is below the phar-
macological dose of Nolvadex® (tamoxifen citrate, 20–40
mg/day) prescribed to women (300–400 μg/kg), assum-
ing an average weight of 70 kg. Moreover, the ovariect-
omized model provides increased sensitivity to estrogen
action in the immature rodent and thus allows for a more
comprehensive assessment of the partial-agonistic activity
of TAM in the uterus.
The physiological effects were comparable between spe-
cies and ligand with EE eliciting the classic uterotrophic
responses while TAM showed decreased efficacy with only
partial agonist activity, as previously reported [22]. How-
ever, the more pronounced induction of luminal epithe-
lial cell height in the rat compared to the mouse was
unexpected. Previous rat studies have not observed
increased efficacy of TAM in inducing luminal epithelial
cell height relative to estrogen [23,24], which may due to
differences in animal age, ovariectomy status or other
study design issues. However, a comparable increase in
TAM LEH induction in rats relative to estrogen was previ-
ously reported as not statistically different [25]. Further-
more, the uterotrophic effects of EE and TAM in
ovariectomized Cynomolgus Macaque monkeys [26]
showed a noticeable increase in TAM induced LEH rela-
tive to EE that was not statistically significant. The similar-
ity in LEH response to higher order mammals/primates
suggests that the rat may be a better model of the human
response, but further study is required.
The partial agonist effects of TAM with regard to its ER-
complex conformation and differential interactions at
specific canonical response elements (including EREs and
AP-1 sites) as well as gene specific promoters (Vitello-
Quantitative Real Time PCR Confirmation of Species-Specific ER Regulation of Ca2 Figure 5
Quantitative Real Time PCR Confirmation of Species-Specific ER Regulation of Ca2. The temporal gene expres-
sion of carbonic anhydrase 2 (designated Car2 in the mouse and Ca2 in the rat and human, hereafter referred to as Ca2 to rep-
resent all orthologs) was further validated by species-conserved and -unique primer sets. The QRT-PCR results confirm the 
microarray results indicating that Ca2 is differentially regulated in the mouse when compared to the rat. This differential regu-
lation was elicited by both EE and TAM. Mouse Ca2 expression is significantly (p < 0.05) induced while rat expression is signif-
icantly (p < 0.05) repressed (n = 5, Tukey's HSD post hoc test), at multiple time points as indicated by the asterisk (*).
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Table 1: Species and Compound Conserved Genes
Maximum Fold Change
Functional Category Gene Symbol Entrez Gene ID (Mm) MmEE RnEE MmTAM RnTAM Timea
Energetics Aldoa 11674 1.36 2.04 1.34 1.75 Sustained
Atp5b 11947 1.70 1.85 1.67 1.69 Sustained
Atp5g1 11951 3.77 2.57 2.86 1.88 Sustained
Ckb 12709 2.72 2.92 1.42 2.04 Mid
Cox7b 20463 0.28 0.49 0.75 0.57 Sustained
Cycs 13063 4.69 3.72 4.22 3.11 Sustained
Ldha 16828 2.60 2.46 2.66 2.20 Sustained
Pgk1 18655 3.77 3.25 2.46 2.93 Sustained
Slc25a4 11739 2.02 1.94 1.53 1.94 Mid
Slc25a5 11740 5.32 3.17 4.31 3.09 Sustained
Txnl2 30926 1.96 2.35 1.45 1.90 Mid/Sustained
Chaperone & Protein Folding Cct7 12468 2.76 2.71 2.18 2.08 Sustained
Hsp90aa 15519 2.65 1.47 3.21 2.69 Mid
Hspa5 14828 4.44 2.35 6.72 2.32 Sustained
Hspd1 15510 3.76 2.97 4.06 2.52 Mid
Hspe1 15528 3.64 3.67 3.43 3.08 Mid
Cell Structure Dynll1 56455 2.33 2.26 1.67 1.73 Sustained
Krt13 16663 2.36 3.48 2.79 3.68 Sustained
Krt8 16691 1.78 2.95 1.30 3.10 Sustained
Serpinh1 12406 3.71 2.80 3.51 2.05 Mid
Tubb2c 227613 1.35 3.07 3.03 2.68 Mid
Cell Signaling App 11820 0.40 0.39 0.48 0.51 Sustained
Cd24a 12484 2.23 4.00 5.00 3.74 Late
Dcn 13179 0.35 0.38 0.50 0.49 Sustained
Igf1 16000 4.50 7.16 4.40 5.92 Sustained
Sepp1 20363 0.26 0.25 0.19 0.31 Mid
Transcription & NA Processing Atf4 11911 4.42 3.27 2.96 2.00 Sustained
Cnot4 53621 3.16 6.33 2.88 5.91 Sustained
Fos 14281 6.38 40.25 4.08 7.86 Early
Hnrpab 15384 3.31 3.17 2.28 2.18 Sustained
Hnrpu 51810 2.22 1.82 1.71 1.49 Sustained
Translation & Protein Turnover Eif1 20918 1.57 2.37 1.41 1.71 Mid
Eif2s2 67204 3.50 1.87 1.82 2.38 Sustained
Psma5 26442 1.64 1.99 1.42 1.70 Mid
Psmb5 19173 3.11 2.31 2.33 1.90 Mid
Uncategorized or Other Armet 315989 9.77 3.67 2.21 3.11 Sustained
C3 12266 3.62 9.27 5.36 4.85 Late
Car3 12350 0.06 0.11 0.12 0.31 Late
Cst3 13010 0.72 0.34 0.61 0.35 Sustained
Hba-a1 15122 0.25 0.40 0.41 0.49 Late
Itm2b 16432 0.52 0.21 0.48 0.35 Mid
Ly6e 17069 1.90 2.49 1.96 1.38 Early/Late
Mgp 17313 0.22 0.40 0.38 0.51 Sustained
Ran 19384 3.23 4.25 3.68 3.19 Mid
Txn1 22166 1.51 2.10 1.64 1.72 Mid
a Early = 2, 4 or 8 hrs, Mid = 8, 12, 18 or 24 hrs, Late = 72 hrs, Sustained = 3 or more consecutive timepoints.BMC Medical Genomics 2009, 2:19 http://www.biomedcentral.com/1755-8794/2/19
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genin, Complement component 3, prolactin) have been
well studied. However, the global gene targets of TAM-ER
complex have not been comprehensively elucidated in the
rodent uterus. Although direct primary ligand-ER effects
can not be deduced from expression profiling alone, our
comparative approach provides evidence of several con-
served responses elicited by two structurally diverse lig-
ands. While EE is absorbed and attains peak plasma
concentration before TAM does [27,28], the difference is
only a matter of hours and the more likely limiting step is
the hydroxylation of TAM to 4-OH-tamoxifen or
endoxifen, which could account for the 10–12 h delay
observed in gene expression response between EE and
TAM. However, as primary gene responses give way to sec-
ondary responses, gene expression cascades are sequen-
tially propagated across time. If the two ligand-receptor
complexes elicit different behaviours at the primary
response genes, it is likely that subsequent differences in
secondary and tertiary responses would also be propa-
gated over time. However, this is not the case as EE and
TAM elicited comparable expression profiles that are
maintained throughout the time course in both species.
This suggests that TAM elicits parallel uterine gene expres-
sion behavior when compared EE, despite the temporal
shift of expression due to pharmacokinetic differences
[29].
An inclusive, multi-step approach to identifying differen-
tially expressed genes was used to ensure conservation of
gene expression between ligand or species could not be
attributed to strict cut offs applied during screening. Com-
parison of gene expression profiles revealed highly similar
sets of genes between species and compounds (Figure 3
and 4). When profiles were aligned and compared on a
quantitative scale, TAM typically elicited a lower fold
change when compared to EE, consistent with its partial
agonist activity. However, four notable species-conserved
orthologs (Hsp90aa1, Slc9a3r1, Acsbg1, Col5a1) were
identified where TAM induction exceeded that of EE. For
example, Slc9a3r1, a cytoskeletal-membrane protein
binding-protein that functions to maintain epithelial cell
structure and polarity [30], was induced 4.1-fold (Rn) and
3.6-fold (Mm) by TAM but only 2.7-fold (Rn) and 3-fold
(Mm) by EE, respectively. Few genes exhibited unique dif-
ferential gene expression suggesting that TAM elicits uter-
otrophic affects through the same target genes affected by
EE (Figure 6). This is significant, as little information is
known about how conformational changes in the SERM-
ER complex affect the number or types of uterine genes
modulated after treatment.
A large number of regulated genes were differentially
expressed across all four data sets, of which, 398 exhibited
comparable patterns of expression [see Additional Files 3,
4, 5, and 6], and likely represent conserved ER-mediated
uterine responses. They were associated with several func-
tional categories including cellular energetics, chaperone
and protein folding, cell structure, cell signaling, tran-
scription and RNA processing, and translation and pro-
tein turnover (Table 1). Although most genes were up
regulated, those associated with the cell cycle and
mitogenic activity were down regulated, consistent with
an overall proliferative response [31,32]. Several of these
conserved early (e.g., Fos and Vegf), mid (e.g., Ccnd1) and
late (e.g., C3) responders responses are known ER targets
regulated via estrogen response elements (EREs), AP-1,
and Sp1 sites. The temporal differences in expression
(between 2 and 72 hrs after treatment) of genes known to
be ER regulated affirms the bi- or multi-phasic activities of
activated ER during uterotrophy [33]. Although the TAM
profiles exhibited a temporal shift for early regulated
genes (Fos and Vegf), genes differentially expressed at 18,
24 and 72 hrs (Ccnd1, Tk1) exhibited little temporal shift.
This suggests a pharmacokinetic difference which is not
applied equally to all responses or is masked by the sus-
tained nature of mid to late gene responses.
TAM perturbs calcium homeostasis causing intracellular
influx of Ca2+ ions which is related to cytotoxic, throm-
Four Way Venn Analysis of Active Genes Figure 6
Four Way Venn Analysis of Active Genes. Each data set 
was converted into ortholog space and processed for activity 
using relaxed criteria prior to analysis using the 4-way Venn 
Diagram Generator http://www.pangloss.com/seidel/Proto-
cols/venn4.cgi. The Venn set was subsequently filtered for 
genes which met the initial, high-stringency criteria to ensure 
robust comparisons. Gene lists for each Venn set are availa-
ble [see Additional File 7].BMC Medical Genomics 2009, 2:19 http://www.biomedcentral.com/1755-8794/2/19
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botic and systemic effects [34,35]. This is believed to be
ER independent, and is suggestive of alternative mecha-
nisms activated only by TAM. However, no differential
gene expression was observed regarding genes involved in
calcium homeostasis, including Ca2+ transporters
Atp2a1, -2a2, -2b1, and -2b2, calcium transporters that
are targets of the calcineurin/Crz1 signaling pathway
which regulates intracellular Ca2+ homeostasis. Moreo-
ver, the increased LEH responsiveness in rat is not
explained by our current data, although this may be due
to differences in genome coverage represented on our
mouse and rat cDNA microarrays. It is also likely that
there are significant species-specific post-transcriptional
differences that are not assessed using gene expression
approaches.
Conclusion
In summary, our parallel study design afforded a robust
comparative analysis of EE and TAM elicited responses in
the rat and mouse uterus. TAM induced UWW and LEH in
a manner consistent with its partial-agonist activity at a
dose equipotent to EE. This suggests that EE and TAM
elicit comparable uterine gene expression profiles despite
conformation differences in the liganded ER complexes,
and that the transcriptional activity via AF-1, which is acti-
vated by both EE and TAM, is sufficient to elicit uterine
differential gene expression. This is consistent with mice
studies with targeted disruption of the ER DNA binding
domain [36], which did not exhibit acute uterotrophy but
still elicited epithelial proliferation and increased LEH. It
also supports the sufficiency of the AF-1 domain alone
(via TAM binding) to mediate uterotrophy. Although dif-
ferences in LEH induction were observed between EE and
TAM, collectively our data suggests that TAM does not
elicit a unique uterine gene expression profile when com-
pared to EE. However, more comprehensive studies are
warranted that would examine the differential expression
of all orthologous rat and mouse genes.
Methods
Husbandry
Experimental designs and methods for the rat tamoxifen
data parallel previously published rat and mouse EE and
mouse TAM studies [21,37]. Briefly, female Sprague-Daw-
ley rats and C57BL/6 mice, ovariectomized on PND 20
and all within 10% of the average body weight were
obtained from Charles River Laboratories (Raleigh, NC)
on day 25. Animals were housed in polycarbonate cages
containing cellulose fibre chip bedding (Aspen Chip Lab-
oratory Bedding, Northeastern Products, Warrensberg,
NY) and maintained at 40–60% humidity and 23°C in a
room with a 12 hrs dark/light cycle (7 am–7 pm). Animals
were allowed free access to de-ionized water and Harlan
Teklad 22/5 Rodent Diet 8640 (Madison, WI), and accli-
matized for 4 days prior to dosing.
Treatments
In dose response studies, animals received three consecu-
tive, daily oral treatments of EE (0.01 to 300 μg/kg) or
TAM (3 to 3000 μg/kg b.w.). Animals were sacrificed 72
hrs after the initial dose. In time course studies animals
were treated once or once daily for three consecutive days
via oral gavage with 100 μg/kg b.w. EE or TAM in 0.1 mL
of sesame oil vehicle (Sigma Chemical, St Louis, MO), (EE
time course treatment in mouse, MmEE; EE time course
treatment in rat, RnEE; EE in mouse, MmEE; TAM in
mouse, MmTAM;). This oral dose was empirically derived
and chosen because it elicited a maximal uterotrophic
response in both species while showing no acute toxic
effects. Animals receiving a single dose were sacrificed 2,
4, 8, 12, 18, or 24 hrs after treatment. Animals receiving
three consecutive, daily doses were sacrificed 72 hrs post
initial dose. An equal number of time-matched vehicle
control (VEH) animals were treated in the same manner,
(n = 8 for MmEE, n = 5 for all others). Doses of EE and
TAM were calculated based on average weights of each
treatment and VEH group prior to dosing. All procedures
were performed with the approval of the Michigan State
University All-University Committee on Animal Use and
Care.
Necropsy
Animals were sacrificed by cervical dislocation and animal
body weights were recorded. The uterine body was dissected
at the border of the cervix and whole uteri were harvested
and stripped of extraneous connective tissue and fat. Whole
uterine weights were recorded before (wet) and after (blot-
ted) being blotted under pressure with absorbent tissues and
were subsequently snap-frozen in liquid nitrogen and stored
at -80°C. Weight due to water was calculated as the differ-
ence between the wet and blotted weights. A small (~5 mm)
section of the right, distal uterine horn was placed in 10%
neutral buffered formalin (NBF; VWR, West Chester, PA) and
stored at RT for at least 24 hrs prior to further processing. Sta-
tistical analysis of wet weight and water content were con-
ducted using a two-way ANOVA with a Tukey's Honestly
Significant Difference post hoc test, p < 0.05 (SAS 9.1, SAS
Institute Inc. Cary, NC).
RNA Isolation
Total RNA was isolated from whole uteri (~20 mg/rat, ~3
mg/mouse) using Trizol® Reagent (Invitrogen, Carlsbad,
CA). Uteri were removed from -80°C storage and imme-
diately homogenized in 1 mL Trizol® Reagent using a
Mixer Mill 300 tissue homogenizer (Retsch, Germany).
Total RNA was isolated according to manufacturer's pro-
tocol and resuspended in The RNA Storage Solution
(Ambion, Austin, TX). Concentration was calculated by
spectrophotometric methods (A260) and purity assessed
by the A260:A280 ratio and by visual inspection of 1 μg on
a denaturing gel.BMC Medical Genomics 2009, 2:19 http://www.biomedcentral.com/1755-8794/2/19
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Histological Processing
NBF-fixed uterine sections were routinely processed and
embedded in paraffin according to standard histological
techniques. Five μm cross-sections were mounted on glass
slides and stained with hematoxylin and eosin. All
embedding, mounting and staining of tissues were per-
formed at the Histology/Immunohistochemistry Labora-
tory, located in the Department of Physiology, of
Michigan State University.
Histopathological and Morphometric Assessment
Histological slides were scored according to standardized
National Toxicology Program (NTP) pathology codes.
Morphometric analyses were performed on cross sections
for each animal using image analysis software (Scion
Image, Scion Corporation, Frederick, MD) and standard
morphometric techniques. Briefly, the contour length of
basal lamina underlying the luminal epithelium (LE) and
corresponding areas of LE was quantified for multiple,
representative sectors of each section. Statistical analyses
on all morphometry data were performed using a two-way
ANOVA with a Tukey's Honestly Significant Difference
post hoc test, n = 5, p < 0.05 (SAS 9.1, SAS Institute Inc.).
Microarray Platform
Rat cDNA arrays were produced in-house using a LION
Bioscience's Rat cDNA library (LION Bioscience, Heidel-
berg Germany) consisting of 8,567 clones representing
5,684 unique genes (Unigene Build #48). Clones were
selected based on their level of annotation as well as
sequence similarity to well annotated human and mouse
genes. Detailed protocols for microarray construction,
labeling of the cDNA probe, sample hybridization and
slide washing can be found at http://dbzach.fst.msu.edu/
interfaces/microarray.html. Briefly, PCR amplified DNA
was robotically arrayed onto epoxy coated glass slides
(SCHOTT Louisville, KY), using an Omnigrid arrayer
(GeneMachines, San Carlos, CA) equipped with 32 (8 ×
4) or 48 (12 × 4) Chipmaker 2 pins (Telechem, Atlanta,
GA) for the rat and mouse arrays, respectively, at the
Genomics Technology Support Facility at Michigan
State University http://www.genomics.msu.edu.
Array Experimental Design
Temporal changes in gene expression were assessed using
an independent reference design in which samples from
EE and TAM treated animals were co-hybridized with
VEH. Comparisons were performed on 3 biological repli-
cates × 2 independent labelings of each sample (incorpo-
rating a dye swap) for each time point. Total RNA (15 μg)
was reverse transcribed in the presence of Cy3- or Cy5-
labeled dUTP (Amersham, Piscataway, NJ) to create fluor-
labeled cDNA, which was purified using QIAquick PCR
purification kit (Qiagen, Valencia, CA). In contrast, note
that mouse array experiments used a 3DNA Array 900
Expression Array Detection Kit (Genisphere, Hatsfield,
PA) using 1 μg of total RNA, according to manufacturer's
specifications, for probe labeling. Cy3- and Cy5-labeled
samples were mixed, vacuum concentrated (~1–2 μl) and
resuspended in 32 μl of hybridization buffer (40% forma-
mide, 4× SSC, 1% SDS) with 20 μg polydA and 20 μg of
mouse COT-1 DNA (Invitrogen) as a competitor. This
probe mixture was heated at 95°C for 2 min and was then
hybridized to the array under a 22 × 40 mm lifterslip (Erie
Scientific Company, Portsmouth, NH) in a light protected
and humidified hybridization chamber (Corning Inc.,
Corning, NY). Samples were hybridized for 18–24 h at
42°C in a water bath. Slides were then washed, dried by
centrifugation and scanned at 635 (Cy5) and 532 nm
(Cy3) on a GenePix 4000B microarray scanner (Molecular
Devices, Union City, CA). Images were analyzed for fea-
ture and background intensities using GenePix Pro 6.0
(Molecular Devices).
Array Data Normalization and Statistical Analysis
Data sets for rat and mouse EE and mouse TAM have been
previously published [21,37] and have been integrated
into the current comparative analysis with rat TAM data.
As previously described with these data sets, rat TAM
microarray data were first examined using a quality assur-
ance protocol prior to further analysis to ensure consist-
ent, high quality data throughout the dose-response and
time course studies prior to normalization and further
analysis [38]. Data were normalized using a semi-para-
metric approach [39]. Model-based t-values were calcu-
lated from normalized data, comparing treated from VEH
responses per time-point. Empirical Bayes analysis was
used to calculate posterior probabilities of activity (P1(t)-
value) on a per gene and time-point basis using the
model-based t-value [40]. Genes were filtered for differen-
tial expression based on the P1(t)-value which indicates
increasing activity as the value approaches 1.0. A two-
tiered set of criteria including a statistical P1(t) > 0.999
and |fold-change| > 1.5 was used as an initial selection fil-
ter of the expression data and defined initial differentially
expressed gene lists in both the rat and mouse. All data
was deposited into dbZach http://dbzach.fst.msu.edu, a
MIAME compliant relational database that ensures proper
data management and facilitates data analysis. Complete
data sets with annotation and P1(t) values are available in
Additional Files 3, 4, 5, and 6.
Expression Data Annotation and Coactivity Analysis
Features refer to unique cDNA clones spotted on the array
and are assigned a GenBank accession number, gene
name, symbol, and Entrez Gene ID where annotation is
available. For the sake of brevity and consistency, genes
are referenced by their official gene symbol as defined by
NCBI. Rat and mouse orthologous gene pairs were
derived from the publicly available Ensembl and Homol-BMC Medical Genomics 2009, 2:19 http://www.biomedcentral.com/1755-8794/2/19
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oGene databases. Comparing gene expression between
species or ligand treatment involved examining the time,
direction, and statistical significance of the change in
expression on a gene by gene basis. Similarities and differ-
ences in gene expression patterns were designated as coac-
tive-similar direction (CAS), coactive-divergent direction
(CAD), displaced active-similar direction (DAS), and dis-
placed active-divergent direction (DAD). Comparative
analysis was conducted using a multivariate correlation-
based visualization application developed in-house.
Additional analysis was performed using the 4-way Venn
Diagram Generator (4VDG, http://www.pangloss.com/
seidel/Protocols/venn4.cgi, which involved applying an
initial relaxed filtering criteria (|fold change| > 1.3 and
P1(t) > 0.99) to each data set, then entering respective Ent-
rez Gene IDs (mouse IDs were used for rat where Homol-
oGene indicated orthology) into the 4VDG. The output
categories were then filtered for only those genes which
met more stringent criteria (|fold change| > 1.5 and P1(t)
> 0.999) at any one time point. Gene lists for each 4-way
Venn category are available [see Additional File 7].
QRT-PCR (Real Time) Analysis
For each sample, 1.0 μg of total RNA was reverse tran-
scribed by SuperScript II using an anchored oligo-dT
primer as described by the manufacturer (Invitrogen). The
resultant cDNA (1.0 μl) was used as the template in a 30
μl PCR reaction containing 0.1 μM each of forward and
reverse gene-specific primers designed using Primer3
(15), 3 mM MgCl2, 1.0 mM dNTPs, 0.025 IU AmpliTaq
Gold and 1× SYBR Green PCR buffer (Applied Biosystems,
Foster City, CA). Gene names, accession numbers, for-
ward and reverse primer sequences and amplicon sizes are
available [see Additional File 8]. PCR amplification was
conducted in MicroAmp Optical 96-well reaction plates
(Applied Biosystems) on an Applied Biosystems PRISM
7500 Sequence Detection System using the following con-
ditions: initial denaturation and enzyme activation for 10
min at 95°C, followed by 40 cycles of 95°C for 15 s and
60°C for 1 min. A dissociation protocol was performed to
assess the specificity of the primers and the uniformity of
the PCR generated products. Each plate contained dupli-
cate standards of purified PCR products of known tem-
plate concentration covering six orders of magnitude to
interpolate relative template concentrations of the sam-
ples from the standard curves of log copy number versus
threshold cycle (Ct). No template controls (NTC) were
also included on each plate. Samples with a Ct value
within 2 SD of the mean Ct values for the NTCs were con-
sidered below the limits of detection. The copy number of
each unknown sample for each gene was standardized to
the geometric mean of house-keeping gene, Rpl7 to con-
trol for differences in RNA loading, quality and cDNA syn-
thesis. Statistical significance of induced or repressed
genes was determined using two-way ANOVA followed by
t-test for VEH treatment comparisons (SAS 9.1, SAS Insti-
tute Inc.). For graphing purposes, the relative expression
levels were scaled such that the expression level of the
time-matched control group was equal to one.
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Mouse TAM Gene Expression Data. data presented represents averaged 
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